Navigation Links
New Study Finds That Gastric Banding Pays for Itself In Approximately Two Years for Patients With Diabetes and Four Years for Patients Without Diabetes
Date:6/22/2011

IRVINE, Calif., June 22, 2011 /PRNewswire/ -- Allergan, Inc. (NYSE: AGN) today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND® Adjustable Gastric Banding System, was offset by reductions in obesity-related medical costs within 2.25 years for surgery eligible patients with diabetes, and within four years of the procedure for all surgery eligible patients.

The study evaluated healthcare claims data from 7,310 patients who had undergone gastric banding compared to claims from a matched control group of 7,306 surgery eligible obese individuals who did not have weight-loss surgery, for the purpose of quantifying the potential savings of gastric banding. The study found that while post-surgery medical costs for the gastric banding group declined slightly, medical costs for the control group continued to rise, thus resulting in significant savings for the banding sample. These findings underscore the critical effect gastric banding has on containing healthcare costs among the target population.  

"Although the gastric banding procedure is associated with upfront costs, our analysis shows that those costs are recovered in a relatively short period of time, particularly for obese patients with diabetes," said study lead author Eric A. Finkelstein, Ph.D., of Duke University and Duke-NUS Graduate Medical School in Singapore. "Although the potential for cost-savings should not drive coverage decisions, some insurance providers are hesitant to cover the costs of bariatric procedures for fear they will break the bank. These results may allay some of those concerns," Finkelstein said.  

Currently, one in three American adults is obese.(1) Due to increased medical expenditures, absenteeism, and presenteei
'/>"/>

SOURCE Allergan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Study Explores Impact of More Uniform Distribution of Endovascular Coils in Cerebral Aneurysm Treatment
2. Study Identifies Large Concentration of Contract Research Assets in Kansas City Region
3. U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries
4. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
5. Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
6. Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery Disease
7. Neurelis Announces Positive Results from Phase 1 Pharmacokinetic Study of NRL-01 (intranasal diazepam)
8. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
9. Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinsons Disease
10. Phase 2 Study of Two Potential CF Therapies — VX-770 and VX-809 — Shows Promising Results in Patients with Most Common Mutation
11. Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinsons Disease to Recombinant DNA Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has ... - Global Trends, Estimates and Forecasts, 2012-2018" report ... Global Electrocardiogram Devices (ECG) sector is ... North America accounts for nearly 36% ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ... 2012-2018"  report to their offering. Global Guidewires sector ... North America accounts for nearly ... Europe claims approximately 25% (2018). ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals Inc. ... that its Board of Directors has elected Mr. Daniel Kazado ... who continues as Chief Executive Officer of Immune. Mr. Kazado ... 2013. Immune,s new Chairman, Mr. Daniel Kazado ... shareholders and to continue to support the strategic vision of ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... April 21 Strativa,Pharmaceuticals, the proprietary products ... PRX ) today announced that its development ... a Phase III,study of Loramyc(R) (miconazole Lauriad(R)) ... candidiasis (OPC)., Top line data show ...
... Nostrum, a privately-held,company based in Edison, ... completed its early, primate, proof-of-concept study for ... SMRX11. Nostrum,s,Symmetrix subsidiary, based in Singapore, is ... from the Institute of Microbial,Technology, Chandigarh, India, ...
Cached Medicine Technology:Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 2Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis 3Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Wittenberg, MD, uses an,investor,s technology to yield the ... 6 When Scottsdale businessman,Warren Kaplan decided a ... had no,idea that an innovative medical product Possis ... gifted interventional radiologist - save his daughter,s life., ...
... Nov. 6 Repligen Corporation,(Nasdaq: RGEN ) ... Phase 2b,clinical trial to evaluate the use of ... bipolar depression. This Phase 2b study is a,multi-center, ... patients with bipolar depression will receive,either RG2417 or ...
... SALT LAKE CITY, Nov. 6 "In a remarkable ... history of cosmetics, women around the,country have been applying ... of fine lines, wrinkles and crows, feet." Five years ... a revolution in the cosmetic,industry: a little-known American stretch-mark ...
... 6 Performance Health Technologies,Inc. (PHT), a leader ... guide and monitor exercise and rehabilitation, announced,today that ... the September 5 edition of "60 Second Science," ... "Virtual Rehabilitation: Wireless Motion Sensor to Help,Treat That ...
... NEW YORK, Nov. 6 According to the ... The African,American community is one of the groups ... diagnosed. With November being National Diabetes Month,Black Expressions(R) ... that raise,awareness about diabetes and offer information about ...
... Salud to Use Pan-Enterprise Search Platform to,Identify ... and SAN FRANCISCO, November 6 /PRNewswire-FirstCall/,-- Autonomy ... global leader in,infrastructure software for the enterprise ... Spain,s most innovative health service,provider, has selected ...
Cached Medicine News:Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 2Health News:Innovative Deep Vein Thrombosis Treatment Yields Priceless Payoff 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 2Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 4Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 2Health News:Happy Birthday, StriVectin! The Skin Cream that Revolutionized the Anti-Aging Market 3Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 2Health News:Performance Health Technologies Garners Additional Media Coverage, Including Scientific American's News Blog 3Health News:National Diabetes Month Book Suggestions From Black Expressions(R) Book Club 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 2Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 3Health News:Leading Spanish Health Service Provider Selects Autonomy for Innovation in Healthcare 4
... and model 1488 active-fixation leads are among ... the unsurpassed handling advantages, performance, and reliability ... active-fixation leads. Implantable with a 7 F ... Tendril SDX lead is designed to lower ...
... Tendril SDX model 1688 and model 1488 ... extendable/retractable pacing leads, offering the unsurpassed handling ... Jude Medical's line of active-fixation leads. Implantable ... body diameter of the Tendril SDX lead ...
... battery-backed up, microprocessor based, quality instrument that monitors ... and displays a chart on its large panel ... or zoomed into and out of, so that ... months can be seen at one time. ...
... Aegis CheckPoint is an automated, wireless, ... and alert system for refrigerator, freezer, ... chart recorders, data loggers and manual ... on an existing PC and comes ...
Medicine Products: